Naslov
Nivolumab induced hypopituitarism – case report

Autori
Lepetić, Petra ; Linarić, Petra ; Jezernik, Dejana ; Kanceljak, Kristina ; Tečić Vuger, Ana ; Pavlović, Mirjana ; Vazdar, Ljubica ; Šeparović, Robert

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Libri Oncologici : Croatian Journal of Oncology / - , 2022, 64-64

Skup
1st Croatian virtual congress of oncology pharmacy

Mjesto i datum
Online, 07.10.2021. - 10.10.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
immune checkpoint inhibitors (ICI), programmed death 1(PD-1) receptor, renal cell carcinoma (RCC), hypopituitarism

Sažetak
Nowadays, immune checkpoint inhibitors (ICI) are a treatment of choice in a wide array of malignancies such as RCC, melanoma, or non - small cell lung carcinoma with significantly improved survival rates. Nivolumab targets programmed death 1 receptor (PD-1) - an effector ligand of immune checkpoint pathways, thus promoting an immunological reaction against cancer cells.Many immunerelated adverse effects are due to specific mechanisms of action.Although hypopituitarism is more frequent following combo therapy (ipilimumab with nivolumab), it rarely occurs in monotherapy with nivolumab. This care report aims to demonstrate occasional, but potentially severe entity that requires appropriate prompt diagnostic and therapeutic interventions. Patients should be closely monitored for a wide range of adverse events, keeping in mind that a wide range of immune-related adverse events can occur. Some of them are potentially severe, deferring treatment and compromising outcomes. At that point, prompt and focused care is needed to resolve the complications and to achieve maximum therapeutic potential.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA